ADIL
Adial Pharmaceuticals, Inc.·Healthcare
1.57
0.641%(+0.01)
Market ClosedLast Updated: — ET
52W L: $1.5452W H: $30.25
Adial Pharmaceuticals, Inc.·Healthcare
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) was the target of a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling 27,868 shares, a drop of 17.2% from the February 12th total of 33,643 shares. Based on an average trading volume of 52,717 shares,
Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3 Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3
Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission for AD04 Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission for AD04
Adial Pharmaceuticals (NASDAQ: ADIL - Get Free Report) and Kaleido Biosciences (NASDAQ: KLDO - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends. Profitability This table compares Adial Pharmaceuticals and
GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today applauded the passage by Congress and signing into law by President Donald J. Trump of the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill, 2026.
Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026 Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026